These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35382145)

  • 1. Iloprost infusion through elastomeric pump in the treatment of Raynaud's phenomenon and digital ulcers.
    Fartura Braga Temido MH; Gomes M; Parente F; Santos L
    J Scleroderma Relat Disord; 2019 Feb; 4(1):NP1-NP4. PubMed ID: 35382145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iloprost infusion through elastomeric pump for the outpatient treatment of severe Raynaud's phenomenon and digital ulcers - a single centre experience.
    Duarte AC; Barbosa L; Santos MJ; Cordeiro A
    Acta Reumatol Port; 2018; 43(3):237-238. PubMed ID: 30414374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA).
    Fraticelli P; Martino GP; Murri M; Mattioli M; Gabrielli A
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):173-178. PubMed ID: 28869415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with bosentan and sildenafil for refractory digital ulcers and Raynaud's phenomenon in a 30-year-old woman with systemic sclerosis: Case report and literature review.
    Rademacher JG; Wincup C; Tampe B; Korsten P
    J Scleroderma Relat Disord; 2020 Jun; 5(2):159-164. PubMed ID: 35382024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.
    Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR
    Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort.
    Silva C; Solanki KK; White DHN
    Rheumatol Immunol Res; 2022 Jun; 3(2):84-89. PubMed ID: 36465326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.
    Linnemann B; Erbe M
    Vasa; 2016; 45(3):201-12. PubMed ID: 27129065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E; Virgilio S; Ghirardi R; Martinelli M
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis.
    Bixio R; Adami G; Bertoldo E; Giollo A; Morciano A; Bertelle D; Orsolini G; Idolazzi L; Rossini M; Viapiana O
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221137125. PubMed ID: 36439640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis.
    Arefiev K; Fiorentino DF; Chung L
    Int J Rheumatol; 2011; 2011():201787. PubMed ID: 22121371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.
    Jokar MH; Baghbani B; Geraylow KR; Shariati J; Mehrad-Majd H; Mirfeizi Z; Hashemzadeh K
    Reumatologia; 2022; 60(6):392-398. PubMed ID: 36683833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.
    Fernández-Codina A; Cañas-Ruano E; Pope JE
    J Scleroderma Relat Disord; 2019 Jun; 4(2):102-110. PubMed ID: 35382396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany].
    Juche A; Siegert E; Mueller-Ladner U; Riemekasten G; Günther C; Kötter I; Henes J; Blank N; Voll RE; Ehrchen J; Schmalzing M; Susok L; Schmeiser T; Sunderkoetter C; Distler J; Worm M; Kreuter A; Horváth ON; Schön MP; Korsten P; Zeidler G; Pfeiffer C; Krieg T; Hunzelmann N; Moinzadeh P
    Z Rheumatol; 2020 Dec; 79(10):1057-1066. PubMed ID: 32040755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.